Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), stated that the vaccine demonstrated high efficacy in preclinical trials and is ready for deployment. It is currently awaiting approval from the Russian Ministry of Health. If approved, the vaccine will initially be available to patients with colorectal cancer, followed by those with glioblastoma and melanoma.
![]() |
Cancer vaccine illustration. Photo: TASS
The vaccine has proven safe for repeated use and effective in reducing tumor size and growth, thereby increasing survival rates in patients.
Developed using mRNA technology, the Russian cancer vaccine trains the patient's immune system to target cancer cells. Consequently, its testing and licensing procedures follow specific protocols.
The state fully funds the vaccine's production, costing over 2,800 USD per dose. It will be provided free of charge to Russian citizens. Russia currently has an estimated 4 million cancer patients and 625,000 new cases annually.
Chi Le (According to RT)